Patents Assigned to Biocon Limited
-
Patent number: 11629120Abstract: The present invention provides for methyl)-4-amino-2R-methyl butanoic acid ethyl ester sodium salt, a novel process for the preparation of crystalline Form B of N-(3-carboxyl-1-oxopropyl)-(4S)-(p-phenylphenylmethyl)-4-amino-2R-methyl butanoic acid ethyl ester sodium salt.Type: GrantFiled: November 5, 2020Date of Patent: April 18, 2023Assignee: BIOCON LIMITEDInventors: Palle Venkata Raghavendra Charyulu, Pratik Rameshchandra Patel, Thirunelimada Devaiah Venu, Reddy Avathu Vidyasagar, Rajmahendra Shanmughasamy
-
Patent number: 11530403Abstract: The present invention discloses rapid and cost-effective method of de-glycosyation of a glycoprotein, wherein, glycoprotein is combined with anionic surfactant and reducing agent and non-ionic surfactant in order to obtain stable denatured glycoprotein. An endoglycosidase is further added to denatured glycoprotein to cleave N-linked glycans in order to obtain de-glycosylated protein. A rapid tool for assessing the protein conformation by partial de-glycosylation is also presented wherein the partial de-glycosylated protein is analysed using capillary electrophoresis (CE-SDS).Type: GrantFiled: November 17, 2017Date of Patent: December 20, 2022Assignee: BIOCON LIMITEDInventors: Anushikha Thakur, Seija Rohil, Shrivardhan Patil, Meenakshi Sudhakaran, Laxmi Adhikary
-
Patent number: 11340238Abstract: The present invention provides an in vitro method for detecting the presence of neutralizing antibodies against recombinant human insulin (rHI) in human serum. It also provides a kit for an in vitro method of detection of the presence of recombinant human insulin (rHI) neutralizing antibodies.Type: GrantFiled: October 15, 2016Date of Patent: May 24, 2022Assignee: BIOCON LIMITEDInventors: Abhishek Kulshrestha, Ravi Shankar Maurya, Sudeep Sabde, Pallavi Hajela, Pawan Kalani, Ramakrishnan Melarkode, Narendra Chirmule
-
Patent number: 11203585Abstract: The present invention provides for novel co-crystals of lenalidomide. The present invention particularly provides for novel cocrystals of lenalidomide with Resorcinol, Methyl paraben and Saccharin. The present invention also provides for the processes for the production of cocrystals of lenalidomide with Resorcinol, Methyl paraben and Saccharin. The present invention further provides for processes for the preparation of crystalline anhydrous lenalidomide Form IV.Type: GrantFiled: March 27, 2020Date of Patent: December 21, 2021Assignee: BIOCON LIMITEDInventors: Ramakrishna Parameswar Bhat, Lankeswararao Matti, Venkata Raghavendracharyulu Palle, VijayBhaskar Reddy Regalla
-
Patent number: 11066439Abstract: The present invention relates to the efficient solid-phase synthesis of liraglutide represented by Formula-I. The present invention relates to an efficient process for the preparation of liraglutide by sequential coupling employing solid phase approach. It involves sequential coupling of protected amino acids to prepare backbone of liraglutide and upon completion of linear sequence, synthesis was extended from lysine side chain by adding ?-glutamic acid and palmitic acid, followed by removal of protective groups, cleavage of the peptide from solid support and purification of crude liraglutide obtained. The present invention also involves the usage of inorganic salts during the coupling, wash with HOBt in DMF solution after Fmoc-deprotection step to suppress the aggregation of peptides and ensure reactions are going for completion, and thus avoid deletion sequences and improve the process yield.Type: GrantFiled: December 9, 2017Date of Patent: July 20, 2021Assignee: Biocon LimitedInventors: Ramu Vasanthakumar Ganga, Nitin Patil, Palle Venkata Raghavendra Charyulu, Castelino Roopa Jasmine, Rambabu Machani, Deepa Shankar Suvarna
-
Patent number: 11059813Abstract: The present invention provides for the dasatinib-thymine co-crystal and dasatinib-adenine co-crystal. The present invention further provides dasatinib-butanediol solvate. The present invention further provides for crystalline dasatinib-(±)-1, 2-Butanediol, crystalline dasatinib (R)-1, 2-Butanediol, crystalline dasatinib (S)-1, 2-Butanediol and crystalline dasatinib (±)-2, 3-Butanediol and processes for preparation thereof. The present invention also provides for a process for preparation of amorphous dasatinib using dasatinib-butanediol solvate. The present invention further provides for the preparation of anhydrous dasatinib. The present invention also provides for a process for preparation of dasatinib monohydrate from anhydrous dasatinib.Type: GrantFiled: July 7, 2018Date of Patent: July 13, 2021Assignee: BIOCON LIMITEDInventors: Ramakrishna Parameshwar Bhat, Jithendrababu Raghunadhachetty, Raghavendracharyulu Venkata Palle, Mariappan Kaliappan, Reddy VijayBhaskar Regalla
-
Patent number: 11040974Abstract: The present invention provides novel crystalline forms B1 & B2 of linagliptin intermediate of structural formula V and methods for production of novel crystalline form of linagliptin intermediate represented by the following structural formula V.Type: GrantFiled: March 27, 2020Date of Patent: June 22, 2021Assignee: BIOCON LIMITEDInventors: Venkata Raghavendracharyulu Palle, Shanmughasamy Rajmahendra, Dharshan Jakkali Chandregowda, Thangarasu Ponnusamy
-
Patent number: 11028168Abstract: The present disclosure relates to methods for treatment and prevention of disease conditions mediated by T-helper 17 (Th17) and/or T-helper 1 (Th1) T lymphocytes (T cells). In particular, the present disclosure relates to use of anti-CD6 antibody for treatment of disease conditions mediated by auto-reactive Th17 and Th1 T lymphocytes. The methods of the present disclosure further have utility in methods for modulating an immune response by suppressing production of the cytokine IL-23R, thereby decreasing inflammation mediated by Th17 cells.Type: GrantFiled: December 10, 2018Date of Patent: June 8, 2021Assignee: BIOCON LIMITEDInventors: Pradip Nair, Ramakrishnan Melarkode, Bala S. Manian, Abhijit Barve, Usha Bughani, Jose Enrique Montero Casimiro
-
Patent number: 10995060Abstract: The present invention provides for crystalline Form B1 of N-(3-carboxyl-1-oxopropyl)-(4S)-(p-phenylphenyl-methyl)-4-amino-2R-methyl butanoic acid ethyl ester sodium salt, crystalline Form B2 of N-(3-carboxyl-1-oxopropyl)-(4S)-(p-phenylphenylmethyl)-4-amino-2R-methyl butanoic acid ethyl ester sodium salt, a novel process for the preparation of crystalline Form B of N-(3-carboxyl-1-oxopropyl)-(4S)-(p-phenylphenylmethyl)-4-amino-2R-methyl butanoic acid ethyl ester sodium salt.Type: GrantFiled: October 28, 2017Date of Patent: May 4, 2021Assignee: BIOCON LIMITEDInventors: Palle Venkata Raghavendra Charyulu, Pratik Rameshchandra Patel, Thirunelimada Devaiah Venu, Reddy Avathu Vidyasagar, Rajmahendra Shanmughasamy
-
Patent number: 10927102Abstract: The present invention provides an industrial method production of amorphous posaconazole. The present invention also relates to a method for production of the posaconazole via and novel crystalline forms of posaconazole intermediate. More particularly the present invention relates to novel crystalline forms of posaconazole intermediate and methods for production of novel crystalline forms of posaconazole intermediate represented by the following structural formula III Which is key intermediate in the production of posaconazole. The present invention also provides for the one pot process for the preparation of amorphous posaconazole using novel crystalline forms of benzyl posaconazole.Type: GrantFiled: October 17, 2019Date of Patent: February 23, 2021Assignee: BIOCON LIMITEDInventors: Palle Venkata Raghavendra Charyulu, Dharshan Jakkali Chandre Gowda, Shanmughasamy Rajmahendra, Manikandan Raman
-
Publication number: 20200377495Abstract: The present invention provides for the dasatinib-thymine co-crystal and dasatinib-adenine co-crystal. The present invention further provides dasatinib-butanediol solvate. The present invention further provides for crystalline dasatinib-(±)-1,2-Butane diol, crystalline dasatinib (R)-1,2-Butanediol, crystalline dasatinib (S)-1,2-Butanediol and crystalline dasatinib (±)-2,3-Butanediol and processes for preparation thereof. The present invention also provides for a process for preparation of amorphous dasatinib using dasatinib-butanediol solvate. The present invention further provides for the preparation of anhydrous dasatinib.Type: ApplicationFiled: July 7, 2018Publication date: December 3, 2020Applicant: Biocon LimitedInventors: Ramakrisna Parameshwar BHAT, Jithendrababu RAGHUNADHACHETTY, Raghavendracharyulu Venkata PALLE, Mariappan KALIAPPAN, Reddy VijayBhaskar REGALLA
-
Patent number: 10669346Abstract: The present invention relates to a humanized IgG1 isotype anti-CD6 antibody (T1h) that binds to the Scavenger receptor cysteine-rich (SRCR) domain 1 (D1) of CD6 present on the surface of thymic epithelial cells, monocytes, activated T cells and a variety of other cells types.Type: GrantFiled: May 9, 2018Date of Patent: June 2, 2020Assignees: BIOCON LIMITED, CENTRO DE INMUNOLOGIA MOLECULARInventors: Ramakrishnan Melarkode, Pradip Nair, Sundaraj David Rajkumar, Kedarnath Nanjund Sastry, Monalisa Chatterji, Laxmi Adhikary, Hema Balasubramanian, Jose Enrique Montero Casimiro, Josefa Lombardero Valladares, Rolando Perez Rodriguez
-
Patent number: 10526279Abstract: The present invention provides a process for the preparation of Teriflunomide (Formula-I). The present invention describes the synthesis of Teriflunomide without isolating the intermediate Leflunomide. Teriflunomide is prepared from 5-Methyl isoxazole-4-carboxylic acid by converting to its acid chloride and coupling with 4-trifluoromethyl aniline to obtain Leflunomide (which is not isolated) followed by ring opening reaction using aq. Sodium Hydroxide to form Teriflunomide. In other words, the process is telescoped from 5-methylisoxazole-4-carbonyl chloride.Type: GrantFiled: June 16, 2016Date of Patent: January 7, 2020Assignee: BIOCON LIMITEDInventors: Venkata Raghavendracharyulu Palle, Ramakrishna Parameshwar Bhat, Mariappan Kaliappan, Jithendra R. Babu, Rajmahendra Shanmughasamy
-
Patent number: 10457668Abstract: The present invention provides an industrial method production of amorphous posaconazole. The present invention also relates to a method for production of the posaconazole via and novel crystalline forms of posaconazole intermediate. More particularly the present invention relates to novel crystalline forms of posaconazole intermediate and methods for production of novel crystalline forms of posaconazole intermediate represented by the following structural formula III Which is key intermediate in the production of posaconazole. The present invention also provides for the one pot process for the preparation of amorphous posaconazole using novel crystalline forms of benzyl posaconazole.Type: GrantFiled: September 22, 2016Date of Patent: October 29, 2019Assignee: BIOCON LIMITEDInventors: Palle Venkata Raghavendra Charyulu, Dharshan Jakkali Chandre Gowda, Shanmughasamy Rajmahendra, Manikandan Raman
-
Patent number: 10385348Abstract: The present invention relates generally to the field of generating fusion proteins to be used in cancer therapy, and more specifically, to nucleotide sequences encoding the fusion proteins, wherein the chimeric fusion proteins comprises at least one targeting moiety and at least one immunomodulatory moiety that counteracts the immune tolerance of cancer cells.Type: GrantFiled: October 27, 2017Date of Patent: August 20, 2019Assignee: BIOCON LIMITEDInventors: Nagaraj Govindappa, Kedarnath Sastry, Maria Melina Soares
-
Publication number: 20190241670Abstract: The present invention relates to compositions and methods useful for the treatment of lupus using a humanized IgG1 anti-CD6 monoclonal antibody (T1h) that binds to the SRCR domain 1 (D1) of CD6 without blocking the interaction of CD6 with the CD6 ligand Activated Leukocyte Cell Adhesion Molecule (ALCAM).Type: ApplicationFiled: October 17, 2017Publication date: August 8, 2019Applicant: Biocon LimitedInventors: Pradip NAIR, Ravindra Belavinakodige SADASHIVARAO, Ramakrishnan MELARKODE
-
Patent number: 10308970Abstract: The present invention relates to a method or process for controlling, inhibiting or reducing protein fucosylation in a eukaryote and/or eukaryotic protein expression system. Said method comprises carrying out the protein expression and/or post-translational modification in the presence of an elevated total concentration of manganese or manganese ions.Type: GrantFiled: November 21, 2017Date of Patent: June 4, 2019Assignee: BIOCON LIMITEDInventors: Pradip Nair, Ramakrishnan Melarkode, Rasika Venkataraman, Laxmi Adhikary, Ankur Bhatnagar, Sunaina Prabhu, Kriti Shukla, Dinesh Baskar, Saravanan Desan, Harish Venkatraman Pai, Jose Enrique Montero Casimiro
-
Patent number: 10189899Abstract: The present disclosure relates to methods for treatment and prevention of disease conditions mediated by T-helper 17 (Th17) and/or T-helper 1 (Th1) T lymphocytes (T cells). In particular, the present disclosure relates to use of anti-CD6 antibody for treatment of disease conditions mediated by auto-reactive Th17 and Th1 T lymphocytes. The methods of the present disclosure further have utility in methods for modulating an immune response by suppressing production of the cytokine IL-23R, thereby decreasing inflammation mediated by Th17 cells.Type: GrantFiled: July 23, 2014Date of Patent: January 29, 2019Assignee: BIOCON LIMITEDInventors: Pradip Nair, Ramakrishnan Melarkode, Bala S. Manian, Abhijit Barve, Usha Bughani, Jose Enrique Montero Casimiro
-
Patent number: 10144934Abstract: The present invention relates generally to the field of generating fusion proteins to be used in cancer therapy, and more specifically, to nucleotide sequences encoding the fusion proteins, wherein the chimeric fusion proteins comprises at least one targeting moiety and at least one immunomodulatory moiety that counteracts the immune tolerance of cancer cells.Type: GrantFiled: February 28, 2017Date of Patent: December 4, 2018Assignee: BIOCON LIMITEDInventors: Nagaraj Govindappa, Kedarnath Sastry, Maria Melina Soares
-
Patent number: 10047134Abstract: The present disclosure relates to a comprehensive model for expression of recombinant peptides by Pichia pastoris. The model uses an easily controllable variable called ‘critical nutrient ratio’ for obtaining a right balance between product synthesis and it's degradation during the fermentation process. The extra cellular concentration of precursor could be increased by about 10 folds and the degradation constants could be reduced by about 10-20 folds for intracellular and extracellular cases respectively by controlling critical nutrient ratio and addition of soya flour hydrolysate and EDTA.Type: GrantFiled: January 10, 2014Date of Patent: August 14, 2018Assignee: Biocon LimitedInventors: Sanjay Tiwari, Gourav Awasthi, Gokul Jothiraman, Arun Chandavarkar